Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CNTX
CONTEXT THERAPEUTICS INC.
NASDAQ
$0.38
▼ DOWN 7.79% (-0.03)

KEY STATISTICS

Market Cap$35.25 M
52w High$3.62
52w Low$0.38
Dividend Yield—
Frequency—
P/E-0.80
Volume3.02M
Shares Out.91.88M

COMPANY

LEADERSHIP

Martin A. Lehr
CHIEF EXECUTIVE
Martin A. Lehr

COMPENSATION 2026

Salary$588,515
Stock Awards$0
Incentive Plan Pay$300,000
All Other Comp.$10,500
Total$1,465,430

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 20, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
15

PRICE TARGET

Target High$6.00
Target Low$4.50
Target Median$5.25
Target Consensus$5.25

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED

PRICE

$0.38 ▼ DOWN 7.79% (−$0.03)
$0.39$0.41$0.429:32 AM10:37 AM11:41 AM12:45 PM1:50 PM2:55 PM3:59 PM0.38

About Context Therapeutics Inc.

https://www.contexttherapeutics.com ↗

Context Therapeutics Inc. is a Philadelphia-based clinical-stage biopharma developing cancer treatments for women, including onapristone extended release and a CLDN6xCD3 bispecific antibody targeting hormone-dependent and gynecologic cancers.

INDUSTRY

Biotechnology

A PRODUCT CONTEXT THERAPEUTICS INC. IS KNOWN FOR

CTIM-76
CTIM-76

CTIM-76 is a clinical-stage bispecific antibody targeting Claudin 6 in solid tumors, currently in Phase 1 trials, and is Context Therapeutics' lead candidate for innovative cancer therapy development.

COMPETITORS

COMPETITOR
BNTX COMPARE
JANX COMPARE
XNCR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
39
LISTED HERE
6
RANKED BY POSITION SIZE
VTI
0.00% · 2.8M
XSU.TO
0.00% · 2.3M
XRS2.F
0.00% · 85.2K
RSSL
0.00% · 44.2K
URTY
0.00% · 3.8K
SC0K.DE
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
88.17%
HOLDERS
70
TOP 12 OF 70 · RANKED BY POSITION SIZE
Bioimpact Capital LLC
14.7M sh · $14.25M
Avidity Partners Management LP
9.0M sh · $8.7M
Blue Owl Capital Holdings LP
7.4M sh · $10.93M
Deep Track Capital, LP
7.4M sh · $19.44M
Nextech Invest Ltd.
7.4M sh · $7.79M
Nextech Invest, Ltd.
7.4M sh · $19.44M
Soleus Capital Management, L.P.
7.0M sh · $18.24M
Octagon Capital Advisors LP
5.3M sh · $13.76M
Great Point Partners LLC
4.7M sh · $6.89M
Franklin Resources Inc
4.0M sh · $5.88M
Vanguard Group Inc
3.8M sh · $5.57M
Marshall Wace, Llp
2.9M sh · $7.72M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score3

INSIDER TRADES

★
DIRECTOR
Stacey Jennifer Evans
Purchase · 45.0K shares
2026-06-24
★
DIRECTOR
Kantoff Philip W.
Purchase · 45.0K shares
2026-06-24
★
DIRECTOR
Smith Karen L.
Purchase · 45.0K shares
2026-06-24
★
DIRECTOR
West Linda
Purchase · 45.0K shares
2026-06-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
Maxim Group BUY D. Boral Capital BUY Guggenheim BUY Piper Sandler OVERWEIGHT HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
STTK$7.04COMPARE
OVID$2.80COMPARE
IFRX$2.23COMPARE
WHWK$4.62COMPARE
MGNX$4.13COMPARE
ORMP$5.03COMPARE
CNTB$2.23COMPARE
KLRS$4.03COMPARE